Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 W ELECTROLYTES versus AMINOSYN II 4 25 W ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 W ELECTROLYTES versus AMINOSYN II 4 25 W ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10 IN PLASTIC CONTAINER.
AMINOSYN 8.5% W/ELECTROLYTES vs AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% with Electrolytes is a crystalline amino acid solution used for parenteral nutrition. It provides essential and non-essential amino acids necessary for protein synthesis, tissue repair, and maintenance of nitrogen balance. Electrolytes are included to maintain acid-base balance and normal cellular function.
Aminogen (amino acids) provide substrate for protein synthesis; dextrose provides caloric energy; electrolytes maintain acid-base and fluid balance; phosphate is essential for cellular metabolism and buffering.
Intravenous infusion: 500 mL to 1000 mL of 8.5% solution (42.5-85 g amino acids) once daily, infused at a rate not exceeding 100 mL/hour.
Intravenous infusion; typical adult dose: 1-1.5 g amino acids/kg/day, with dextrose providing 10% final concentration. Adjusted to meet protein and caloric needs.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for essential amino acids and 0.5-2 hours for non-essential amino acids, reflecting rapid distribution and metabolism in healthy adults. In renal or hepatic impairment, half-life may be prolonged.
Amino acids have a terminal elimination half-life of approximately 1.5–2 hours in healthy adults, reflecting rapid metabolic clearance. In renal impairment, half-life may be prolonged due to accumulation of nitrogenous waste.
Amino acids are primarily eliminated via metabolism (deamination, transamination) and incorporation into proteins. Unmetabolized amino acids are excreted renally (approximately 5-10% of administered dose, depending on renal function and infusion rate). Fecal and biliary excretion are negligible (<1%).
The components of AMINOSYN II (amino acids) and dextrose are primarily metabolized; excess nitrogen is excreted renally as urea. Dextrose is completely oxidized. Electrolytes are excreted mainly renally. Biliary/fecal elimination is negligible for amino acids and dextrose (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution